96 related articles for article (PubMed ID: 30914563)
1. [XELIRI plus Bmab Therapy as a Secondary Treatment for Recurrent Colorectal Cancer with Long-Term Survival].
Yukimoto R; Fukunaga M; Konishi K; Matsuno Y; Nakai S; Takiguchi N; Honda S; Saito A; Takeoka T; Okada K; Ota H; Yokoyama S; Kobayashi K
Gan To Kagaku Ryoho; 2019 Feb; 46(2):369-371. PubMed ID: 30914563
[TBL] [Abstract][Full Text] [Related]
2. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
4. [Two Cases of Rectal Cancer Resected Curatively after Chemotherapy with CapeOX plus Bmab].
Chiku T; Sano W; Hashiba T; Togawa Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1647-9. PubMed ID: 26805125
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
6. [A case of recurrent rectal cancer successfully treated for a long period with capecitabine plus oxaliplatin and bevacizumab therapy].
Iwata N; Ishikawa T; Takahashi H; Baba H; Masuda D; Okazaki S; Matsuyama T; Ishiguro M; Kobayashi H; Iida S; Uetake H; Sugihara K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2008-10. PubMed ID: 24393995
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
García Alfonso P; Muñoz Martin A; Alvarez Suarez S; Blanco Codeidido M; Mondejar Solis R; Tapia Rico G; López Martín P; Martin M
Onkologie; 2013; 36(6):363-7. PubMed ID: 23774151
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Mizushima T; Fukunaga M; Sueda T; Ikeda M; Kato T; Kim HM; Kudo T; Murata K; Nishimura J; Hata T; Matsuda C; Yamamoto H; Doki Y; Mori M
Cancer Chemother Pharmacol; 2017 Jul; 80(1):81-90. PubMed ID: 28510802
[TBL] [Abstract][Full Text] [Related]
9. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Recurrent Colon Cancer Successfully Treated with Capecitabine plus Bevacizumab].
Naito A; Murata K; Kagawa Y; Kawai K; Sakamato T; Inatome J; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Egawa C; Takeda Y; Kato T; Tamura S
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1811-1813. PubMed ID: 29394784
[TBL] [Abstract][Full Text] [Related]
11. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
14. [Long-Term Survival in a Case of Colon Cancer with Peritoneal Dissemination and Ovarian Metastasis after Multimodality Therapy].
Tanida T; Noura S; Ogino T; Nagase H; Noguchi K; Hirota M; Oshima K; Tomimaru Y; Kawase T; Imamura H; Akagi K; Iwazawa T; Dono K
Gan To Kagaku Ryoho; 2020 Apr; 47(4):676-678. PubMed ID: 32389981
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Colon Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine/Oxaliplatin plus Bevacizumab].
Suematsu Y; Ishibashi Y; Hiratsuka M; Suda H; Takahashi M; Saito H; Omori K; Morita A; Wakabayashi K; Ito Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2100-2. PubMed ID: 26805277
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
Miyamae Y; Takahashi K; Igarashi T; Tanaka K; Takahashi N; Hirai K; Tsukagoshi H; Ogawa H; Yoshinari D; Sunose Y; Takeyoshi I
Gan To Kagaku Ryoho; 2014 Jun; 41(6):737-41. PubMed ID: 25129085
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
18. [A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab].
Ito S; Ichikawa R; Kure K; Honjo K; Aoki J; Okazawa Y; Mizukoshi K; Ro H; Kawai M; Takehara K; Okubo H; Ishiyama S; Sugimoto K; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tomiki Y; Sakamoto K
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1425-8. PubMed ID: 25434448
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Ocvirk J; Rebersek M; Boc M
Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
